The clinical trial is sponsored by The Affiliated Hospital of Xuzhou Medical University and aims to evaluate the safety and efficacy of a combination regimen of BTK inhibitors and Anti-CD19 CAR-T cells in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma (B-NHL). Given the increasing prevalence of B-NHL and the limitations of current treatment options, this study addresses a significant unmet medical need. If successful, the results could position the combination therapy as a competitive option in the oncology market, particularly against existing therapies such as monoclonal antibodies and other CAR-T cell therapies. The trial's outcomes may also influence market dynamics and investor interest in CAR-T and BTK inhibitor technologies.